ULTRAGENYX PHARMACEUTICAL INC. Increase (Decrease) in Accounts Receivable
ULTRAGENYX PHARMACEUTICAL INC. (RARE) reported Increase (Decrease) in Accounts Receivable of $43.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-08-05
- ULTRAGENYX PHARMACEUTICAL INC. increase (decrease) in accounts receivable for the quarter ending 2026-06-30 was $62.00M, a 376.92% increase year-over-year.
- ULTRAGENYX PHARMACEUTICAL INC. increase (decrease) in accounts receivable for the quarter ending 2026-03-31 was -$19.00M.
- ULTRAGENYX PHARMACEUTICAL INC. increase (decrease) in accounts receivable for the quarter ending 2025-12-31 was $33.83M, a 60.79% increase year-over-year.
- ULTRAGENYX PHARMACEUTICAL INC. increase (decrease) in accounts receivable for the quarter ending 2025-09-30 was -$5.83M.
- ULTRAGENYX PHARMACEUTICAL INC. increase (decrease) in accounts receivable for fiscal 2025 was $31.00M, a 8.82% decline from fiscal 2024.
- ULTRAGENYX PHARMACEUTICAL INC. increase (decrease) in accounts receivable for fiscal 2024 was $34.00M, a 47.83% increase from fiscal 2023.
- ULTRAGENYX PHARMACEUTICAL INC. increase (decrease) in accounts receivable for fiscal 2023 was $23.00M, a 90.59% increase from fiscal 2022.
- ULTRAGENYX PHARMACEUTICAL INC. increase (decrease) in accounts receivable for fiscal 2022 was $12.07M, a 122.16% increase from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 3 month as first filed | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 6 month as first filed | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 9 month as first filed | Increase (Decrease) in Accounts Receivable 12 month | Increase (Decrease) in Accounts Receivable 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $62.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $43.00M 10-Q · filed 2026-08-05 | $76.83M derived: sum of 3 quarters · filed 2026-08-05 | $71.00M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2026-03-31 | -$19.00M 10-Q · filed 2026-05-06 | $14.83M derived: sum of 2 quarters · filed 2026-05-06 | $9.00M derived: sum of 3 quarters · filed 2026-05-06 | $22.00M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-12-31 | $33.83M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | $28.00M derived: sum of 2 quarters · filed 2026-02-18 | $41.00M derived: sum of 3 quarters · filed 2026-08-05 | $31.00M 10-K · filed 2026-02-18 | ||||
| 2025-09-30 | -$5.83M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $7.17M derived: sum of 2 quarters · filed 2026-08-05 | -$2.83M 10-Q · filed 2025-11-05 | $18.21M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-06-30 | $13.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $3.00M 10-Q · filed 2026-08-05 | $2.59M 10-Q · filed 2025-08-06 | $24.04M derived: sum of 3 quarters · filed 2026-08-05 | $14.25M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2025-03-31 | -$10.00M 10-Q · filed 2026-05-06 | -$10.06M 10-Q · filed 2025-05-07 | $11.04M derived: sum of 2 quarters · filed 2026-05-06 | $1.25M derived: sum of 3 quarters · filed 2026-05-06 | -$908.00K derived: sum of 4 quarters · filed 2026-05-06 | |||
| 2024-12-31 | $21.04M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | $11.25M derived: sum of 2 quarters · filed 2026-02-18 | $9.09M derived: sum of 3 quarters · filed 2026-02-18 | $34.00M 10-K · filed 2026-02-18 | $33.60M 10-K · filed 2025-02-19 | |||
| 2024-09-30 | -$9.79M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$11.95M derived: sum of 2 quarters · filed 2025-11-05 | $12.96M 10-Q · filed 2025-11-05 | $12.17M derived: sum of 4 quarters · filed 2026-02-18 | ||||
| 2024-06-30 | -$2.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $22.75M 10-Q · filed 2025-08-06 | $21.96M derived: sum of 3 quarters · filed 2026-02-18 | $28.16M derived: sum of 4 quarters · filed 2026-02-18 | ||||
| 2024-03-31 | $24.91M 10-Q · filed 2025-05-07 | $24.12M derived: sum of 2 quarters · filed 2026-02-18 | $30.32M derived: sum of 3 quarters · filed 2026-02-18 | $45.40M derived: sum of 4 quarters · filed 2026-02-18 | ||||
| 2023-12-31 | -$790.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | $5.41M derived: sum of 2 quarters · filed 2026-02-18 | $20.49M derived: sum of 3 quarters · filed 2026-02-18 | $23.00M 10-K · filed 2026-02-18 | $22.78M 10-K · filed 2024-02-21 | |||
| 2023-09-30 | $6.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $21.28M derived: sum of 2 quarters · filed 2024-11-06 | $23.79M 10-Q · filed 2024-11-06 | $32.88M derived: sum of 4 quarters · filed 2025-02-19 | ||||
| 2023-06-30 | $15.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-02 | $17.59M 10-Q · filed 2024-08-02 | $26.68M derived: sum of 3 quarters · filed 2025-02-19 | $20.75M derived: sum of 4 quarters · filed 2025-02-19 | ||||
| 2023-03-31 | $2.51M 10-Q · filed 2024-05-03 | $11.60M derived: sum of 2 quarters · filed 2025-02-19 | $5.67M derived: sum of 3 quarters · filed 2025-02-19 | $14.61M derived: sum of 4 quarters · filed 2025-02-19 | ||||
| 2022-12-31 | $9.10M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-19 | $3.17M derived: sum of 2 quarters · filed 2025-02-19 | $12.10M derived: sum of 3 quarters · filed 2025-02-19 | $12.07M 10-K · filed 2025-02-19 | ||||
| 2022-09-30 | -$5.93M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | $3.01M derived: sum of 2 quarters · filed 2023-11-03 | $2.97M 10-Q · filed 2023-11-03 | $6.04M derived: sum of 4 quarters · filed 2024-02-21 | ||||
| 2022-06-30 | $8.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-04 | $8.90M 10-Q · filed 2023-08-04 | $11.97M derived: sum of 3 quarters · filed 2024-02-21 | $12.66M derived: sum of 4 quarters · filed 2024-02-21 | ||||
| 2022-03-31 | -$33.00K 10-Q · filed 2023-05-05 | $3.04M derived: sum of 2 quarters · filed 2024-02-21 | $3.73M derived: sum of 3 quarters · filed 2024-02-21 | $3.41M derived: sum of 4 quarters · filed 2024-02-21 | ||||
| 2021-12-31 | $3.07M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-21 | $3.76M derived: sum of 2 quarters · filed 2024-02-21 | $3.44M derived: sum of 3 quarters · filed 2024-02-21 | $5.43M 10-K · filed 2024-02-21 | ||||
| 2021-09-30 | $693.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $369.00K derived: sum of 2 quarters · filed 2022-11-03 | $2.36M 10-Q · filed 2022-11-03 | -$2.35M derived: sum of 4 quarters · filed 2023-02-17 | ||||
| 2021-06-30 | -$324.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-29 | $1.67M 10-Q · filed 2022-07-29 | -$3.04M derived: sum of 3 quarters · filed 2023-02-17 | $1.31M derived: sum of 4 quarters · filed 2023-02-17 | ||||
| 2021-03-31 | $1.99M 10-Q · filed 2022-05-06 | -$2.72M derived: sum of 2 quarters · filed 2023-02-17 | $1.64M derived: sum of 3 quarters · filed 2023-02-17 | -$4.35M derived: sum of 4 quarters · filed 2023-02-17 | ||||
| 2020-12-31 | -$4.71M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-17 | -$358.00K derived: sum of 2 quarters · filed 2023-02-17 | -$6.34M derived: sum of 3 quarters · filed 2023-02-17 | -$9.84M 10-K · filed 2023-02-17 | ||||
| 2020-09-30 | $4.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | -$1.63M derived: sum of 2 quarters · filed 2021-11-03 | -$5.13M 10-Q · filed 2021-11-03 | $4.58M derived: sum of 4 quarters · filed 2022-02-15 | ||||
| 2020-06-30 | -$5.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-03 | -$9.48M 10-Q · filed 2021-08-03 | -$17.95M 10-Q · filed 2020-07-30 | $220.00K derived: sum of 3 quarters · filed 2022-02-15 | $2.46M derived: sum of 4 quarters · filed 2022-02-15 | |||
| 2020-03-31 | -$3.50M 10-Q · filed 2021-05-05 | $6.20M derived: sum of 2 quarters · filed 2022-02-15 | $8.44M derived: sum of 3 quarters · filed 2022-02-15 | $13.71M derived: sum of 4 quarters · filed 2022-02-15 | ||||
| 2019-12-31 | $9.70M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | $11.94M derived: sum of 2 quarters · filed 2022-02-15 | $17.20M derived: sum of 3 quarters · filed 2022-02-15 | $20.10M 10-K · filed 2022-02-15 | ||||
| 2019-09-30 | $2.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-27 | $7.50M derived: sum of 2 quarters · filed 2020-10-27 | $10.40M 10-Q · filed 2020-10-27 | $14.00M derived: sum of 4 quarters · filed 2021-02-12 | ||||
| 2019-06-30 | $5.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-30 | $8.16M 10-Q · filed 2020-07-30 | $11.76M derived: sum of 3 quarters · filed 2021-02-12 | $3.49M derived: sum of 4 quarters · filed 2021-02-12 | ||||
| 2019-03-31 | $2.90M 10-Q · filed 2020-05-07 | $6.50M derived: sum of 2 quarters · filed 2021-02-12 | -$1.77M derived: sum of 3 quarters · filed 2021-02-12 | $11.98M derived: sum of 4 quarters · filed 2021-02-12 | ||||
| 2018-12-31 | $3.60M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-12 | -$4.67M derived: sum of 2 quarters · filed 2021-02-12 | $9.08M derived: sum of 3 quarters · filed 2021-02-12 | $7.58M 10-K · filed 2021-02-12 | ||||
| 2018-09-30 | -$8.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $5.48M derived: sum of 2 quarters · filed 2019-11-06 | $3.98M 10-Q · filed 2019-11-06 | $9.15M 10-Q · filed 2018-11-06 | ||||
| 2018-06-30 | $13.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-02 | $12.25M 10-Q · filed 2019-08-02 | ||||||
| 2018-03-31 | -$1.50M 10-Q · filed 2019-05-07 | |||||||
| 2017-12-31 | $5.17M 10-K · filed 2020-02-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |